Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Market Trends
CHAPTER TWO: INTRODUCTION
- Background
- Cancer: Diagnosis and Management of a Chronic Disease
- Point of View
CHAPTER THREE: TRENDS AND ISSUES IN COMMERCIALIZATION
- Background
- Demographics of Cancer, Worldwide
- Cancer Testing in the World-Screening and Government Supported Programs
- An Aging World Population
- United States of America
- Europe
- People' s Republic of China
- India
- Canada
- Reimbursement and Commercialization of Novel Tests
- Consumerism and Web-Based Test Services
- Regulatory Requirements of New Products
- Strategic Alliances-Rx-Dx and Dx-Dx Partnerships
- From Research to the Clinical Lab
CHAPTER FOUR: TECHNOLOGICAL TRENDS ENABLING THE FUTURE OF CANCER DIAGNOSTICS
- Background
- Biomarker Revolution
- The Promise of Personalized Medicine
- Miniaturization and Multiplexed Biological Assays
- The Search for Non-Invasive Tools
- Serum
- Saliva
- Transdermal/Optical
- Breath
- Hair
- Sputum
- Role of Immunoassays in Cancer Management
- New Technologies Applied To Cancer Diagnostics
- Proteomics, Mass Spectroscopy and the Role of the Immune System
- Methylated Gene (meDNA) Patterns
- Circulating Cell-Free Nucleic Acids
- RNA-Ribonucleic Acid
- Stem Cell Markers
- The Role of In Vivo Diagnostics-In vivo Cellular and Molecular Imaging
CHAPTER FIVE: MARKET ANALYSIS-IN VITRO TESTS FOR CANCER
- Background
- World Segments of the Market for Cancer Diagnostics
- Companies and Products
- Screening Tests
- DR-70
- HAAH
- ECPKA
- The Cancer Profile
- Cancer-Specific Tests
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Lung Cancer
- Ovarian Cancer
- Prostate Cancer
CHAPTER SIX: MARKET ANALYSIS-CANCER TESTS IN IVD SEGMENTS
- Cancer Diagnostics and IVD Markets
- The Market For Cancer Tests In Clinical Chemistry
- The Market For Cancer Tests in Immunoassays-Lab-Based & Rapid
- The Market for Cancer Tests in Histology and Cytology
- The Future of the Pap Smear & HPV Testing
- IHC/ISH and Digital Cytometry
- The Market for Tissue Microarrays
- The Market for Cancer Tests in Flow Cytometry
- The Market for Cancer Tests and Image Cytometry
- The Market for Circulating Tumor Cells in Cancer Diagnostics
- The Market for Molecular Assays in Cancer
- The Market for Pharmacodiagnostics Tests in Cancer
- The Market for Biochips and Arrays in Cancer Diagnostics
- Cancer Sample Preparation Techniques
- The Commercial Outlook for Cancer Diagnostics
CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS
- Conclusions
- Conclusion One
- Conclusion Two
- Conclusion Three
- Conclusion Four
- Conclusion Five
- Conclusion Six
- Unmet Market Needs
- Unmet Need One
- Unmet Need Two
- Unmet Need Three
CHAPTER EIGHT: THE TOP TIER IVD COMPANIES AND THEIR INVESTMENT IN CANCER
- Abbott Diagnostics
- Recent Revenue History
- Key Comment
- Details
- Molecular Histology
- PCR
- Immunoassays
- Beckman Coulter, Inc.
- Recent Revenue History
- Key Comment
- Details
- Flow Cytometry
- Cancer Immunoassays
- FOB
- Becton Dickinson & Company
- Recent Revenue History
- Key Comment
- Details
- bioMerieux Inc.
- Recent Revenue History
- Key Comment
- Details
- Bio-Rad Laboratories Inc.
- Inverness Medical Innovations, Inc.
- Ortho Clinical Diagnostics
- Roche Diagnostics
- Siemens Medical Solutions Diagnostics
- Recent Revenue History
- Key Comment
- Details
- Sysmex Corporation
- Recent Revenue History
- Key Comment
- Details
CHAPTER NINE: NEW ENTRANTS AND NOVEL PRODUCT DEVELOPERS
- 20/20GeneSystems Inc.
- 454 Life Sciences Corporation
- A&G Pharmaceutical
- AdnaGen AG
- Affymetrix Inc.
- Agendia B.V.
- Agilent Technologies Inc.
- Alethia Biotherapeutics Inc.
- Almac Diagnostics (formerly ArraDx)
- Althea Technologies, Inc.
- Ambrilia Biopharma Inc.
- AMDL, Inc.
- American Diagnostica Inc.
- Aperio Technologies, Inc.
- Applied Genomics, Inc. (AGI)
- Applied Imaging Corp./Genetix
- Asuragen, Inc.
- AsymmetRx, Inc.
- AviaraDx (formerly Arcturus Biosciences)
- AVIVA Biosciences Corporation
- BioCurex, Inc.
- BioGenex Laboratories, Inc.
- BioImagene, Inc.
- Biomoda, Inc.
- BioMosaics
- BioNanomatrix
- Biophysical Corp.
- BioServe
- Biosite Incorporated
- BIOVIEW, Inc.
- Bostwick Laboratories, Inc.
- Bruker BioSciences Corporation
- CCC Diagnostics LLC
- Cancer Genetics, Inc.
- Cangen Biotechnologies, Inc.
- Celera
- Celerus Diagnostics
- Cellumen, Inc.
- CeMines, Inc.
- ChemSensing
- Clarient Inc. (formerly ChromaVision)
- CombiMatrix Molecular Diagnostics (CMDX)
- CompuCyte Corporation
- Correlogic Systems, Inc.
- CytoCore, Inc. (formerly Molecular Diagnostics, Inc.)
- Cytyc Corporation
- Dako A/S
- diaDexus Inc.
- DiaGenic ASA
- DiagnoCure
- Diamics, Inc.
- Digene Corporation (Acquired by Qiagen)
- DNA Direct, Inc.
- DxS
- eGene Inc.
- Epigenomics AG
- EXACT Sciences Corporation
- eXagen Diagnostics, Inc.
- Exiqon A/S
- Falcon Genomics, Inc.
- Fermiscan Holdings Limited (FER)
- Fluidigm Corporation
- Fujirebio Diagnostics. Inc. (FDI)
- GeneNews Limited (formerly ChondroGene Limited)
- GenoMed, Inc.
- Genomic Health
- Genoptix Inc.
- Gen-Probe Incorporated
- Genzyme Corporation
- Greiner Bio-One International AG
- Gynecor
- Health Discovery Corporation
- HistoRx, Inc,
- Ikonisys Inc.
- Illumina
- ImmunArray Ltd.
- Immunicon Corporation
- Immunotope, Inc.
- InterGenetics, Inc.
- Invirion Diagnostics, LLC
- Ipsogen
- Kronus Inc.
- Laboratory Corporation of America Holdings (LabCorp)
- Luminex Corporation
- MacroArray Technologies, LLC
- Matritech
- MDS/Molecular Devices Corporation
- Med BioGene, Inc. (MBI)
- Menssana Research, Inc.
- Micronics Inc.
- Miraculins Inc.
- Modern Technology Corp.
- MolecularMD
- MonoGen
- Monogram Biosciences Inc. (formerly Virologic, Inc.)
- mtm laboratories AG
- Myriad Genetics, Inc.
- NeoMatrix, LLC
- NorChip
- NorDiag ASA
- Nuvera Biosciences
- Olympus Life and Material Science Europa, GMBH
- Onco Detectors International LLC
- Oncolab Inc.
- OncoMethylome Sciences S.A.
- Onconome, Inc. (formerly Tessera Diagnostics)
- One Cell Systems, Inc.
- Orion Genomics
- Oxford Genome Sciences Ltd. (OGeS)
- OXIS International
- Pacific Edge Biotechnology Ltd. (PEB)
- Panacea Pharmaceuticals, Inc.
- Pathwork Diagnostics (formerly Predicant Biosciences)
- Perceptronix Medical Inc.
- PerkinElmer, Inc.
- Perlegen Sciences, Inc.
- PersonaDX
- Power3 Medical Products, Inc.
- Precision Therapeutics
- Predictive Biosciences
- PreMD Inc.
- Primagen Holding B.V.
- Proteome Systems Limited
- Provista Diagnostics (formerly Biomarker Technologies LLC)
- Qiagen N.V.
- Quest Diagnostics Incorporated
- RainDance Technologies, Inc. (RDT)
- Rational Therapeutics
- Response Genetics, Inc.
- Rosetta Genomics Ltd.
- Rubicon Genomics, Inc.
- Rules-Based Medicine, Inc.
- Saladax Biomedical, Inc. (SBI)
- Signet Laboratories, Inc.
- Source MDx
- Targeted Diagnostics & Therapeutics, Inc. (TDT)
- Targeted Molecular Diagnostics, LLC (TDM)
- Tripath Imaging, Inc.
- US LABS
- Ventana Medical Systems. Inc.
- Veridex, LLC
- Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.)
- Vision BioSystems Ltd/Danaher Corp.
- Vitatex Inc.
- Wako Chemicals USA
- WaveSense LLC
- Xenomics, Inc.
- Xytos Inc.
- Zila Inc.
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: Market Summary Worldwide Market for In Vitro Cancer Diagnostics
2004-2009
CHAPTER THREE: TRENDS AND ISSUES IN COMMERCIALIZATION
- Table 3-1: Major Cancer Incidence Estimates by Cancer Type and Geographic
Market Development (More Developed vs Less Developed) 2000
- Table 3-2: Worldwide Major Cancer Incidence and Mortality Estimates by
Cancer Type, 2000
- Table 3-3: Old-Age Dependency Ratios Comparative Projections by Leading
Country 2000, 2025
- Table 3-4: Selected DTC Cancer Tests
- Table 3-5: Selected Company Alignments for Cancer Diagnostics, 2005 - 2007
- Table 3-6: Selected Agreements Between Companies and Reference Laboratories
- Table 3-7: Selected Tests Offered by Company Accredited Laboratories
- Table 3-8: Selected IVDs used in Drug Development
CHAPTER FOUR: TECHNOLOGICAL TRENDS ENABLING THE FUTURE OF CANCER DIAGNOSTICS
- Table 4-1: Selected Tumor Markers as Applied to Specific Cancers and Drugs
- Table 4-2: Selected Chemotherapy Resistance Tests
- Table 4-3: Selected Arrays and Biochip Tests for Cancer
- Table 4-4: Selected Non-Invasive Cancer Tests (Company, Sample, Test
Details, Marketing Status)
- Table 4-5: Selected Methylated DNA Tests (Company, Technology, Test
Details, Marketing Status)
- Table 4-6: Selected RNA-Based Cancer Tests
CHAPTER FIVE: MARKET ANALYSIS-IN VITRO TESTS FOR CANCER
- Table 5-1: Cancer Demographics: Populations, Cancer Incidence, Share of
Incidence, and Share of IVD Cancer Market by Geographic Region 2005
- Table 5-2: World Cancer Test Sales by Geographic Region (North America,
Europe, Japan, Rest of World) 2007-2012
- Table 5-3: Cancer Diagnostics and the Top Tier IVD Companies Segments of
Participation 2005
- Table 5-4: Revenues of Selected Cancer Diagnostic Companies 2001-2005
- Table 5-5: Selected Breast Cancer Test Innovations
- Table 5-6: Selected FOB Test Innovations
- Table 5-7: Selected Prostate Cancer Test Innovations (Company, Test
Details, Marketing Status)
CHAPTER SIX: MARKET ANALYSIS-CANCER TESTS IN IVD SEGMENTS
- Table 6-1: Worldwide Market for Selected Cancer In Vitro Diagnostics
Revenues and Growth Rate by Testing Segment (Histology/Cytology, Immunoassays,
Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, Circulating
Tumor Cells, Pharmacodiagnostics) 2007-2012
- Table 6-2: Selected Tissue Function Clinical Chemistry Tests
- Table 6-3: Major Players For Clinical Chemistry Analyzers And Reagents
- Table 6-4: Lab-Based Cancer Immunoassay Sales 2004-2009
- Table 6-5: Potential Cancer Biomarkers
- Table 6-6: Selected Cancer Immunoassay Innovations
- Table 6-7: Worldwide Rapid Cancer Test Sales by Test Category (Fecal
Occult Blood, PSA, H. pylori, NMP22, Other) 2004-2009
- Table 6-8: Worldwide Histology/Cytology Sales by Test Type (Traditional
non-Pap, Pap, IHC, ISH) 2004-2009
- Table 6-9: Top Vendors of Traditional Histology Stains
- Figure 6-1: Geographical Distribution of Pap Testing Volume (in millions
of tests) by Region (U.S., Europe, Japan, ROW)
- Table 6-10: Selected Automated Pap Systems
- Table 6-11: Selected HPV test innovators
- Table 6-12: Selected IHC and ISH Product Companies
- Table 6-13: Major Protein and Molecular Markers Used in Tissue Staining
- Table 6-14: Selected Digital Pathology Systems
- Figure 6-2: The Market for Tissue Microarrays in Clinical Labs 2007-2012
- Table 6-15: Selected Laser Microdissection Instruments
- Table 6-16: Selected Flow Cytometry Innovation (Company, Technology
Details, Marketing Status)
- Figure 6-3: The World Market for Clinical Flow Cytometry 2007-2012
- Figure 6-4: The World Market for Clinical Image Cytometry Systems,
Reagents, and Consumables 2007-2012
- Table 6-17: Selected Circulating Tumor Cell Products (Company, Technology,
Product Details, Marketing Status)
- Figure 6-5: The World Market for Commercial CTC-Based Diagnostic Tests
2007-2012
- Table 6-18: Selected Molecular Tests for Cancer
- Figure 6-6: The World Market for Commercial Pharmacodiagnostics Cancer
Tests 2007-2012
- Table 6-19: Selected Cancer Pharmacodiagnostic Tests (Company, Test
Details, Marketing Status)
- Figure 6-7: World Market for DNA Test Sample Preparation Reagents
- Figure 6-8: Technology Penetration Forecast for Cancer IVDs 2007-2025
|
Related Report
|
View Cart
